Serum IL-17 and postmenopausal osteoporosis

Abstract

Background: Osteoporosis is a bone condition that makes bones thininer and more fragile because of reduced bone density and it puts people at risk of fractures, especially of the hip, spinal vertebrae and wrist. Objective: This study will highlighted the role of IL-17 in postmenopausal osteoporosis. Patients and methods: This study applied on 84 includes subjects (42 postmenopausal osteoporosis patient and 42 of healthy control group), conducted from December 2014 to March 2015 to measure the IL-17 serum level by using ELISA kit. Results: In osteoporotic postmenopausal women the mean of serum IL-17 was (0.49pg/ml) and it is significantly higher than that of healthy group (0.09pg/ml). Conclusion: Serum IL-17 was significantly elevated in osteoporotic postmenopausal women when compared to healthy postmenopausal women.

Serum interleukin-17 and estradiol levels in postmenopausal women in relation to osteoporosis

“…Same results were also reported by AL-Tai [18] who evaluated IL-17 in 84 postmenopausal females and concluded that serum IL-17 was significantly high-up in osteoporotic postmenopausal when compared to healthy postmenopausal women. Furthermore, Zhao et al [19] reported higher serum concentrations of IL-17, with increased IL-17-producing CD4+ T cells, as well as mRNA levels of IL-17 in CD4+ T cells in osteoporotic postmenopausal women than postmenopausal healthy controls.…”